Neurology Central

Risk of Alzheimer’s may be raised by hormone therapy for prostate cancer

People with prostate cancer who are taking androgen deprivation therapy (ADT) may be at a higher risk of developing Alzheimer’s disease or dementia compared with people who do not receive the therapy.

Within the study, which has been published in JAMA, researchers analyzed the association between ADT exposure and diagnosis of Alzheimer’s disease or dementia among elderly men with prostate cancer. Of the 154,089 men sampled in the study, 62,330 received ADT within 2 years of their prostate cancer diagnosis and 91,759 did not.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.